Please login to the form below
Roche's checkpoint inhibitor fails pivotal urothelial cancer trial
Phase 3 trial shows no effect on disease-free survival and misses its primary endpoint
Epizyme wins FDA approval for epithelioid sarcoma treatment
Phase 2 clinical trial shows response rates outweigh risks
AZ’s Imfinzi scores orphan drug status in liver cancer
Company is looking to gain approval in the first-line advanced setting
Immuno-oncology, personalised medicine continues to drive pharma sector
New GlobalData survey identifies key trends impacting the industry
NantKwest rockets on promising pancreatic cancer data
One patient demonstrated a complete response following treatment
Lilly ends $1.4bn deal with immuno-oncology biotech NextCure
Lilly paid $25m upfront on top of a $15m equity investment
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
Outperformed rival across all primary and secondary endpoints
Roche and Illumina partner on genomics for cancer diagnostics
Will leverage genomics system to match optimal cancer treatment
BMS expands collaboration with Nektar, sending shares soaring
Adds research programmes in an additional two cancer types
Adopting a creative IP approach towards biotech clusters
Why big pharma paradigm needs to change
-
A unique ecosystem How life science and healthcare clusters are driving innovation
-
Riding the wave of digital disruptionThe challenges and rewards of meeting consumer expectations
-
Boehringer bolsters NASH pipeline with Enleofen link-upAgrees to pay up to €1bn for each new marketed product
-
Pfizer signs $507m cancer deal with Effector TherapeuticsCollaboration is focused on research into evasive oncogenic target
-
Keytruda claims first place in bladder cancer raceStays ahead of rivals in the PD-1/PD-L1 inhibitor class
-
Novartis reveals positive efficacy data for Xolair follow-upNext-generation treatment is more effective than current therapy
-
Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trialShares shot up more than 50% in wake of announcement
-
Keytruda doesn’t extend survival in small cell lung cancerUnlikely to extend use into the first-line setting
-
Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancerConfirmatory trial strengthens claim in therapy area
-
F-star hires ex-BMS immuno-oncology leader
New CMO to oversee development of lead candidate
-
Lilly appoints Maura Dickler as VP of late phase oncology developmentShe will join the pharma firm from the Memorial Sloan Kettering Cancer Center
-
Metrion Biosciences establishes scientific advisory board
The board will provide scientific oversight and strategic advice to Metrion
-
Dr Sotirios Stergiopoulos leaves Shire for IpsenHe becomes the French biopharma’s chief medical officer
-
Linda Law joins Advicenne as US VP, clinical development and med affairsShe will oversee the biopharma’s developments with its dTRA candidate
Latest research appointments
Featured jobs
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Vice President
-
Competitive Salary Offered
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Director or Senior Account Director
-
Salary TBC
-
Consultant
-
competitive salary
Subscribe to our email news alerts
- Lilly will aim for one $1bn-$5bn deal per quarter in 2020
- Novartis gets EU approval for multiple sclerosis therapy Mayzent
- Immuno-oncology, personalised medicine continues to drive pharma sector
- NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
- FDA delays decision on Intercept's NASH drug by three months
- Novartis gets EU approval for multiple sclerosis therapy Mayzent
- New coronavirus sees drug developers scramble to develop a vaccine
- Sanofi completes acquisition of immuno-oncology specialist Synthorx
- Roche's checkpoint inhibitor fails pivotal urothelial cancer trial
- Epizyme wins FDA approval for epithelioid sarcoma treatment
- Pharma Brand Planners' Blog (Part 8)
- Happy Chinese New Year 2020 - The Year of The Rat
Latest intelligence
- Happy Chinese New Year 2020 - The Year of The Rat
- A fond farewell to The Year of the Pig...
- White Paper for download - Explaining the price of your product
- In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
- OPEN Health expands offering with the launch of a new Learning & Development specialist team
- Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Quick links
Infographics
